Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 8Metastatic Castration-resistant Prostate Cancer 2Prostatic Neoplasms, Castration-Resistant 1Prostate Adenocarcinoma 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Lymphatic Metastasis 1Hormone Refractory Prostate Cancer 1Carcinoma, Renal Cell 1Bone Metastatic Castration-resistant Prostate Cancer 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Magnetic Resonance Spectroscopy 4Specimen Handling 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Indocyanine Green 2Conversion to Open Surgery 2Cisplatin 2Artificial Intelligence 2tislelizumab 1radium Ra 223 dichloride 1peposertib 1pembrolizumab 1lncRNA LNMAT1, human 1encorafenib 1cabozantinib 1binimetinib 1avelumab 1alovudine 1X-Rays 1Technetium-99 1Technetium 1Surgical Procedures, Operative 1Sentinel Lymph Node Biopsy 1Robotic Surgical Procedures 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiation Dose Hypofractionation 1Propranolol 1Platinum Compounds 1Platinum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphatic Metastasis × radium Ra 223 dichloride × 1 year × Clear all
NCT04071236 2026-05-13

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

National Cancer Institute (NCI)

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡